CSPC Pharmaceutical Group Limited (CHJTF)
USD 0.64
(0.0%)
USD 0.64
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 30.13 Billion USD | -5.3% |
| 2022 | 3.31 Billion USD | 1.43% |
| 2021 | 3.26 Billion USD | 20.62% |
| 2020 | 2.7 Billion USD | 16.95% |
| 2019 | 2.31 Billion USD | 29.83% |
| 2018 | 1.78 Billion USD | 49.18% |
| 2017 | 1.19 Billion USD | 46.93% |
| 2016 | 813.7 Million USD | 20.79% |
| 2015 | 673.64 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 5.15 Billion CNY | 0.0% |
| 2024 Q1 | 6.49 Billion CNY | 20.63% |
| 2023 Q2 | 1.62 Billion USD | -70.62% |
| 2023 FY | 3.13 Billion USD | -5.3% |
| 2023 Q4 | 5.38 Billion CNY | -3.06% |
| 2023 Q3 | 5.55 Billion CNY | 242.59% |
| 2023 Q1 | 5.51 Billion CNY | 251.9% |
| 2022 Q2 | 824.97 Million CNY | -9.98% |
| 2022 Q4 | 1.56 Billion USD | -72.7% |
| 2022 Q3 | 5.74 Billion CNY | 596.24% |
| 2022 Q1 | 916.46 Million CNY | 6.29% |
| 2022 FY | 3.31 Billion USD | 1.43% |
| 2021 Q4 | 862.25 Million CNY | 8.38% |
| 2021 Q2 | 827.07 Million CNY | 4.54% |
| 2021 Q3 | 795.61 Million CNY | -3.8% |
| 2021 FY | 3.26 Billion USD | 20.62% |
| 2021 Q1 | 791.16 Million CNY | 22.11% |
| 2020 FY | 2.7 Billion USD | 16.95% |
| 2020 Q4 | 647.91 Million CNY | -12.34% |
| 2020 Q3 | 739.09 Million CNY | 6.4% |
| 2020 Q2 | 694.65 Million CNY | 8.62% |
| 2020 Q1 | 639.5 Million CNY | 10.67% |
| 2019 Q4 | 577.82 Million CNY | 1.33% |
| 2019 Q3 | 570.22 Million CNY | -1.4% |
| 2019 Q2 | 578.31 Million CNY | 1.04% |
| 2019 FY | 2.31 Billion USD | 29.83% |
| 2019 Q1 | 572.36 Million CNY | 24.28% |
| 2018 FY | 1.78 Billion USD | 49.18% |
| 2018 Q4 | 460.55 Million CNY | 6.37% |
| 2018 Q1 | 448.18 Million CNY | 25.32% |
| 2018 Q3 | 432.96 Million CNY | 2.95% |
| 2018 Q2 | 420.56 Million CNY | -6.16% |
| 2017 Q2 | 274.86 Million CNY | 7.95% |
| 2017 FY | 1.19 Billion USD | 46.93% |
| 2017 Q4 | 357.63 Million CNY | 15.11% |
| 2017 Q3 | 310.69 Million CNY | 13.03% |
| 2017 Q1 | 254.62 Million CNY | 18.37% |
| 2016 Q2 | 203.2 Million CNY | 7.98% |
| 2016 Q3 | 206.89 Million CNY | 1.82% |
| 2016 Q1 | 188.18 Million CNY | 6.92% |
| 2016 Q4 | 215.1 Million CNY | 3.97% |
| 2016 FY | 813.7 Million USD | 20.79% |
| 2015 FY | 673.64 Million USD | 0.0% |
| 2015 Q4 | 176 Million CNY | 6.56% |
| 2015 Q3 | 165.17 Million CNY | -4.42% |
| 2015 Q2 | 172.8 Million CNY | 8.3% |
| 2015 Q1 | 159.55 Million CNY | 11.28% |
| 2014 Q4 | 143.38 Million CNY | 5.59% |
| 2014 Q3 | 135.79 Million CNY | 0.47% |
| 2014 Q1 | 125.5 Million CNY | 14.12% |
| 2014 Q2 | 135.15 Million CNY | 7.68% |
| 2013 Q2 | 94.52 Million CNY | -9.24% |
| 2013 Q3 | 95.24 Million CNY | 0.76% |
| 2013 Q4 | 109.98 Million CNY | 15.47% |
| 2013 Q1 | 104.14 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | 13.129% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 12.167% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -268104.779% |
| Novartis AG | 34.18 Billion USD | 11.846% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -3953.7% |